Section Arrow
SCYX.NASDAQ
- SCYNEXIS Inc
Quotes are at least 15-min delayed:2026/08/20 19:28 EDT
After Hours
Last
 5.23
+0.01 (+0.19%)
Bid
5.05
Ask
5.59
High 5.23 
Low 5.15 
Volume 126 
Regular Hours (Closed)
Last
 5.22
+0.07 (+1.36%)
Day High 
5.28 
Prev. Close
5.15 
1-M High
5.54 
Volume 
24.70K 
Bid
5.05
Ask
5.59
Day Low
5.1024 
Open
5.1024 
1-M Low
3.53 
Market Cap 
51.24M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 5.09 
20-SMA 4.69 
50-SMA 4.41 
52-W High 10.48 
52-W Low 3.53 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.91/-1.86
Enterprise Value
52.93M
Balance Sheet
Book Value Per Share
6.73
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
20.60M
Operating Revenue Per Share
13.64
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
HIMSHims & Hers Health31.86+0.77+2.48%-- 
After Hours 31.64 -0.22 -0.69%
AKBAAkebia Therapeutics0.9194+0.034+3.84%-- 
After Hours 0.9273 +0.0079 +0.86%
CGCCanopy Growth Corp1.05+0.01+0.96%-- 
After Hours 1.05 0 0.00%
AMLXAmylyx Pharmaceuticals39.66+1.06+2.75%-- 
After Hours 39.65 -0.01 -0.03%
HLNHaleon plc9.87----20.04PE
After Hours 9.8507 -0.0193 -0.20%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.